Riskpilot← Back to searchSign inGet full accessInject Pharma Sweden AB
ABIn liquidationOrg 5590021464Manufacture of pharmaceutical preparations · NACE 2120Est. 20151 employees
Revenue 2023
SEK 0
EBITDA margin
—
-7654% vs 2022
Equity ratio
100.0%
Financial strength
Net profit 2023
SEK -18,4M
-5554% vs 2022
| Revenue | SEK 0 | — |
| EBITDA | SEK -18,4M | -7654% |
| Net profit | SEK -18,4M | -5554% |
| Total assets | SEK 610K | +1319% |
| Equity | SEK 610K | +5183% |
| Employees | 1 | — |
Legal name
Inject Pharma Sweden AB
Org number
5590021464
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
29 januari 2015
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av likvidatorn likvidatorsuppleanten externa firmatecknaren
Company purpose
Bolaget skall bedriva tillverkning av läkemedel, anordningar för administrering av läkemedel och forskning avseende läkemedel samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 15 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −938 | −1 201 | −7 890 | −237 | −18 377 |
| Depreciation & amort. | −42 | −91 266 | −42 | −88 | −0 |
| EBIT | −980 | −92 467 | −7 932 | −325 | −18 377 |
| Net financials | 24 | — | −2 | — | — |
| Profit before tax | −957 | −92 467 | −7 934 | −325 | −18 377 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −957 | −92 467 | −7 934 | −325 | −18 377 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 67 762 | 8 317 | 426 | 43 | 610 |
| Equity | 60 714 | −3 753 | 313 | −12 | 610 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 7 048 | 12 070 | 113 | 55 | 0 |
| Total debt | 7 048 | 12 070 | 113 | 55 | — |
EBITDA margin
-1837700000.0%
This company
15.8%
Market median
-11631012758% vs market
20192023
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20192023
Return on equity
-3012.6%
This company
18.4%
Market median
-16473% vs market
20192023
Net profit margin
-1837700000.0%
This company
8.1%
Market median
-22687654421% vs market
20192023
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192023
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20192023
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
JA Liquidator | Liquidator | 2023 |
AM External Signatory | External Signatory | 2023 |
WL Liquidator | Liquidator | 2023 |
ME Audit | Audit | 2023 |
AC Auditor Substitute | Auditor Substitute | 2023 |
| Former (2) | ||
HL Chief Executive Officer | Chief Executive Officer | 2021 – 2021 |
JR Chief Auditor | Chief Auditor | 2020 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Former (13) | ||
| Board of Directors | 2023 – 2023 | |
| Board of Directors | 2022 – 2023 | |
| Deputy Board Member | 2020 – 2020 | |
| Board of Directors | 2021 – 2023 | |
| Board of Directors | 2020 – 2021 | |
| Deputy Board Member | 2023 – 2023 | |
| Board of Directors | 2020 – 2021 | |
| Chairman | 2020 – 2022 | |
| Chairman | 2020 – 2020 | |
| Chairman | 2020 – 2020 | |
| Board of Directors | 2020 – 2020 | |
| Chairman | 2022 – 2023 | |
| Board of Directors | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Inject Pharma Sweden AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jan Anders Fredrik Lovén | Liquidator | 0 companies |
| Anna Matilda Sjödin | External Signatory | 0 companies |
| Wendy Lissette Fahlgren | Liquidator | 0 companies |
| Hans Lennart Svanborg | Chief Executive Officer | 0 companies |
| Mattias Eriksson | Audit | 0 companies |
| Jennifer Rock Baley | Chief Auditor | 0 companies |
| Ann Charlott Bouvin | Auditor Substitute | 0 companies |
| Jan Totte Dahlin | Board of Directors | 0 companies |
| Christopher Anthony Hirst | Board of Directors | 0 companies |
| Anna Christina Flodin | Deputy Board Member | 0 companies |
| Carl Olof Torkel Gren | Board of Directors | 0 companies |
| Anna Torun Lovisa Krantz | Board of Directors | 0 companies |
| Gerd Ulla Marina Jonsson | Deputy Board Member | 0 companies |
| Carl-Johan Spak | Board of Directors | 0 companies |
| Per Martin Linse | Chairman | 0 companies |
| Lars Åke Martin | Chairman | 0 companies |
| Mats Göte Uno Persson | Chairman | 0 companies |
| Per Olof Kjell Johansson | Board of Directors | 0 companies |
| Markus Tomas Puusepp | Chairman | 0 companies |
| Josefine Emma Elvira Vestlund | Board of Directors | 0 companies |